THORACIC AND ESOPHAGEAL
Five decades of progress in surgical oncology: Tumors of the lung and esophagus
Valerie W. Rusch MD, FACS,
Corresponding Author
Valerie W. Rusch MD, FACS
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Correspondence Valerie W. Rusch, MD, FACS, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Email: [email protected]
Search for more papers by this authorValerie W. Rusch MD, FACS,
Corresponding Author
Valerie W. Rusch MD, FACS
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Correspondence Valerie W. Rusch, MD, FACS, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Email: [email protected]
Search for more papers by this authorAbstract
During the past 50 years, there has been a remarkable transformation in the management of lung and esophageal cancers. Improved methods of diagnosis, better staging and patient selection for surgery, the advent of minimally invasive approaches to resection, decreasing operative mortality, greater insights into tumor biology, and the development of effective multimodality therapies and precision medicine have contributed to this transformation. Progress has been most notable in lung cancer.
CONFLICT OF INTEREST
Dr. Rusch reports institutional clinical trial funding from Genentech; travel reimbursement from Intuitive Surgical for robotic mentoring.
Open Research
DATA AVAILABILITY STATEMENT
Data Availability Statement is not available.
REFERENCES
- 1Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. Am Rev Respir Dis. 1984; 130: 555-560.
- 2National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
- 3de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020; 382(6): 503-513.
- 4Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound guided transbronchial needle aspiration compared to mediastinoscopy for medistinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011; 142: 1393-1400.
- 5Kalchiem-Dekel O, Connolly JG, Lin I-H, et al. Shape-sensing robotic-assisted bronchoscopy in the diagnosis of pulmonary parenchymal lesions. Chest. 2021; 161(2): 572-582.
- 6Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer. Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e211S-e250S.
- 7Rizk NP, Ghanie A, Hsu M, et al. A prospective trial comparing pain and quality of life measures after anatomic lung resection using either thoracoscopy or thoracotomy. Ann Thorac Surg. 2014; 98(4): 1160-1166.
- 8Lim E, Batchelor TJP, Dunning J, et al. Video-assisted thoracoscopic or open lobectomy in early-stage lung cancer. NEJM Evidence. 2022; 1(3). doi:10.1056/EVIDos2100016
- 9Yang H-X, Woo KM, Sima CS, et al. Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer. Ann Surg. 2017; 265: 431-437.
- 10Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022; 386(21): 1973-1985.
- 11Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995; 60: 615-622.
- 12Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small cell lung cancer (JCOG0802WJOG4607L): a multicentre, open-lael, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022; 399: 1607-1617.
- 13Lou F, Sima CS, Rusch VW, Jones DR, Huang J. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg. 2014; 98(5): 1755-1761.
- 14Keshava HB, Tan KS, Dycoco J, et al. Long-term assessment of efficacy with a novel Thoracic Survivorship Program for patients with lung cancer. J Thorac Cardiovasc Surg. 2022; 1634: 1645-1653.
- 15Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993; 55: 1365-1374.
- 16Rusch VW, Parekh KR, Leon L, et al. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg. 2000; 119: 1147-1153.
- 17Bilsky MH, Vitaz TW, Boland PJ, Bains MS, Rajaraman V, Rusch VW. Surgical treatment of superior sulcus tumors with spinal and brachial plexus involvement. J Neurosurg. 2002; 97(3 Suppl): S301-S309.
- 18Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (intergroup trial 0160). J Clin Oncol. 2007; 25: 313-318.
- 19McCormack P, Bains MS, Beattie EJ Jr, Martini N. New trends in skeletal reconstruction after resection of chest wall tumors. Ann Thorac Surg. 1981; 31: 45-52.
- 20Weyant MJ, Bains MS, Venkatraman E, et al. Results of chest wall resection and reconstruction with and without rigid prosthesis. Ann Thorac Surg. 2006; 81: 279-285.
- 21Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374: 379-386.
- 22Kunitoh H, Kato H, Tsuboi M, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small cell lung cancers: report of Japan Clinical Oncology Group Trial 9806. J Clin Oncol. 2008; 26: 644-649.
- 23Pao W, Miller VA. Epidermal growth factor receiptor mutations, small-molecule diase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005; 23(11): 2556-2568.
- 24Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020; 383(18): 1711-1723.
- 25Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018; 378: 2078-2092.
- 26Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018; 379: 2342-2350.
- 27Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cnacer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 389: 1344-1357.
- 28Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018; 378: 1976-1986.
- 29Chaft JE, Oezkan F, Kris MG, et al. Neoadjuvant treatment of non-small cell lung cancer with atezolizumab. Nat Med. Forthcoming 2022.
- 30Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72: 7-33.
- 31Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of patients with potentially operable carcnoma of the thoracic esopahgus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007; 133: 738-745.
- 32Vimolratana M, Sarkaria IS, Goldman DA, et al. Two-year quality of life outcomes after robotic-assisted minimally invasive and open esophagectomy. Ann Thorac Surg. 2021; 112: 880-889.
- 33Markar SR, Ni M, Gisbertz SS, et al. Implementation of minimally invasive esophagectomy from a randomized controlled trial setting to national practice. J Clin Oncol. 2020; 38(19): 2130-2139.
- 34Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcome following resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004; 198: 42-50.
- 35Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326: 1593-1598.
- 36van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074-2084.
- 37Carr RA, Hsu M, Harrington CA, et al. Induction FOLFOX and PET-directed chemoradiation for locally advanced esophageal adenocarcinoma. Ann Surg. Published online August 13, 2021. doi:10.1097/SLA.0000000000005163
- 38Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): A multicentre, randomised, phase 3 trial. Lancet Oncol. 2022; 23: 259-269.
- 39Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021; 384: 1191-1203.
Citing Literature
